Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 1, 2006, Pages 31-44

  Vethe, N T ^a,b   Mandla, R ^a,b   Line, P D ^a   Midtvedt, K ^a   Hartmann, A ^a   Bergan, S ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Immunosuppressive agents; IMPDH; Kidney transplantation; MMF; MPA; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetics

Indexed keywords

GUANINE NUCLEOTIDE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; BLOOD CELL; CELL ACTIVITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LYMPHOCYTE; MALE; PRIORITY JOURNAL;

ADULT; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 32344446094     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510500420259     Document Type: Article

References (26)

1. Barten MJ, van Gelder T, Gummert JF, Boeke K, Shorthouse R, Billingham ME, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002;2:719-32.
2. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
3. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47.
4. Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004;364:503-12.
5. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-6.
6. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969;113:515-24.
7. Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I, et al. Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001;34:543-9.
8. Albrecht W, Storck M, Pfetsch E, Martin W, Abendroth D. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit 2000;22:283-94.
9. Griesmacher A, Weigel G, Seebacher G, Muller MM. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem 1997;43:2312-7.
10. Montero C, Duley JA, Fairbanks LD, McBride MB, Micheli V, Cant AJ, et al. Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirin-treated patients using a high performance liquid chromatography linked method. Clina Chim Acta 1995;238:169-78.
11. Glander P, Hambach P, Braun KP, Fritsche L, Waiser J, Mai I, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003;41:470-6.
12. Weigel G, Griesmacher A, Zuckermann AO, Laufer G, Mueller MM. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 2001;69:137-44.
13. Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999;65:640-8.
14. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996;62:666-72.
15. Mandla R, Line PD, Midtvedt K, Bergan S. Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. Ther Drug Monit 2003;25:407-14.
16. Bergan S. TDM: Report concentration, Css, rather than area under the curve, AUC. Ther Drug Monit 2003;25:743.
17. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002;13:759-68.
18. Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico N, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001;15:402-9.
19. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000;22:169-73.
20. Mourad M, Malaise J, Chaib ED, De Meyer M, Konig J, Schepers R, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001;47:88-94.
21. Jain J, Almquist SJ, Ford PJ, Shlyakhter D, Wang Y, Nimmesgern E, et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol 2004;67:767-76.
22. Dayton JS, Lindsten T, Thompson CB, Mitchell BS. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol 1994;152:984-91.
23. Escobar-Henriques M, Daignan-Fornier B. Transcriptional regulation of the yeast GMP synthesis pathway by its end products. J Biol Chem 2001;276:1523-30.
24. Grinyo JM, Gil-Vernet S, Cruzado JM, Caldes A, Riera L, Seron D, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003;16:820-7.
25. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004;4:2045-51.
26. Quemeneur L, Gerland LM, Flacher M, Ffrench M, Revillard JP, Genestier L. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 2003;170:4986-95.